secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001493152-24-014866
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025
--------------------------------------------------------------------------------

- Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.
- Osher Capital converts $621,000 debentures into 823.86 shares of Series B Convertible Preferred Stock.
- Each Series B share is convertible into 125.63 common shares, subject to anti-dilution adjustments.
- Brio and Osher amend additional debentures: maturity extended to March 31, 2025; principal increased to $125k and $316,350 respectively.
- Additional automatic conversion of $1,856,566 aggregate debentures into Series B Preferred upon NASDAQ listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000149315224014866/0001493152-24-014866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000149315224014866/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer